Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.47 |
| ▸ | CNR1 | P21554 | 1/20 | 0.45 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.43 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.43 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.43 |
| ▸ | MMP8 | P22894 | 1/20 | 0.43 |
| ▸ | RRM1 | P23921 | 1/20 | 0.42 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.41 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.40 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.40 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13810574 | 0.85 | CA1 (0.53) | CA1CNR1GNAI3GNAO1GNAI1 | |
| SCHEMBL28100557 | 0.83 | GNAI3 (0.58) | CA1CNR1GNAI3GNAO1GNAI1 | |
| SCHEMBL14874696 | 0.83 | GNAI3 (0.58) | CA1CNR1GNAI3GNAO1GNAI1 | |
| SCHEMBL28052076 | 0.83 | GNAI3 (0.58) | CA1CNR1GNAI3GNAO1GNAI1 | |
| SCHEMBL28052266 | 0.83 | GNAI3 (0.58) | CA1CNR1GNAI3GNAO1GNAI1 | |
| SCHEMBL18950344 | 0.83 | EPHX1 (0.52) | CA1CNR1GNAI3GNAO1GNAI1 | |
| SCHEMBL11181600 | 0.83 | GNAI3 (0.54) | CA1CNR1GNAI3GNAO1GNAI1 | |
| SCHEMBL28285001 | 0.83 | GNAI3 (0.58) | CA1CNR1GNAI3GNAO1GNAI1 | |
| SCHEMBL10033567 | 0.80 | TSHR (0.42) | MMP8TSHR | |
| SCHEMBL28328772 | 0.80 | DPP7 (0.62) | CNR1GNAI3GNAO1GNAI1MMP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11072585-B2 | Fluorinated lysyl oxidase-like 2 inhibitors and uses thereof | PHARMAKEA, INC. (US) | 2021-07-27 | — | — | US | disclosed |
| US-20200115341-A1 | FLUORINATED LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF | PHARMAKEA, INC. | 2020-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200115341-A1 | FLUORINATED LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF | LOXL2, LOXL1, LOX | CA1 4197/4885CNR1 3610/4885GNAI3 3792/4885 |
| US-11072585-B2 | Fluorinated lysyl oxidase-like 2 inhibitors and uses thereof | LOXL2, LOXL1, LOX | CA1 4197/4885CNR1 3610/4885GNAI3 3792/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.